 |
 |
 |
| BioBusiness Asia 2008 Tentative Program |
|
| July 22 (Tuesday)
|
| 08:30-09:00 |
Registration |
| 09:00-09:30 |
Opening Ceremony (Grand Ballroom £L, 3rd Floor) |
Global Trend Session
Session Chair: Dr. Chung-Cheng Liu, General Director, Biomedical Engineering Research Laboratory, ITRI |
| 09:30-10:20 |
 |
| Raju Kucherlapat |
|
|
Genetics and Genomics in Clinical Medicine
Dr. Raju Kucherlapati, Genetics Dept., Harvard Medical School, Center for Genetics and Genomics |
|
| 10:20-10:40 |
Break |
| 10:40-11:30 |
 |
| Timothy Rodell |
|
|
25 Years of Biotech - Evolution of Financing, Partnering and the Importance of Asia
Dr. Timothy Rodell, CEO and President, GlobeImmune, Inc. |
|
| 11:30-12:20 |
 |
| David Bernstein |
|
|
Streamlining Outsourced Drug Development ¡V Maximizing the Utilization of Global Contract Organizations
Dr. David Bernstein, Vice President, Pharmaceutical Sciences and Regulatory Compliance, Bernstein CMC Regulatory Consulting |
|
| 12:20-14:00 |
Luncheon Session - TaiGen Biotechnology "Business Model and Pipeline"
Session Chair: Dr. Chung-Cheng Liu, General Director, Biomedical Engineering Research Laboratory, ITRI
Dr. Ming-Chu Hsu, Chairman & CEO, TaiGen Biotechnology Co., Ltd. |
Business Model and Strategy Session
Session Chair: Dr. Ming-Chi Wu, President, Development Center for Biotechnology |
| 14:00-14:30 |
 |
| Susan Pond |
|
|
Overview of the Australian Biotechnology Sector
Dr. Susan Pond, CEO, Johnson & Johnson Research Pty Ltd |
|
| 14:30-15:00 |
 |
| Tony Hickson |
|
|
Imperial Innovations Group Plc - A Different Approach to Technology Transfer
Mr. Tony Hickson, Head of Bioscience, Imperial Innovations Group PLC |
|
| 15:00-15:30 |
 |
| Chen-Lung Steve Lin |
|
|
From Bench to Bedside, and to Desk -- A Change of Mindset
Dr. Chen-Lung Steve Lin, Chair, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College |
|
| 15:30-15:50 |
Break |
| 15:50-16:50 |
Panel Discussion
| Moderator |
| |
Dr. Ming-Chi Wu, President, Development Center for Biotechnology |
| Panelists |
| |
Dr. Susan Pond, CEO, Johnson & Johnson Research Pty Ltd.
Mr. Tony Hickson, Head of Bioscience, Imperial Innovations Group PLC
Dr. Chen-Lung Steve Lin, Chair, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College
Dr. Hardy W. Chan, Executive Vice President & Chief Scientific Officer, ScinoPharm Taiwan Ltd.
Dr. Uwe Peukert, Director, Global External Research & Development, Eli Lilly& Co |
|
| 16:50-18:00 |
Exhibition & Cocktail Reception |
| 18:00-20:30 |
BBA Conference Banquet |
|
|
| July 23 (Wednesday) |
Investor and Business Partnering Session
Session Chair: Dr. Hong-Jen Chang, Chairman and CEO, YFY Biotech Management Company |
| 09:00-09:30 |
 |
| Elka Nir |
|
|
Global trends and challenges in Medical Devices - VC investments
Ms. Elka Nir, Managing Director, Giza Venture Capital |
|
| 09:30-10:10 |
 |
| Axel Polack |
|
|
VC Challenges for Selecting Biopharmaceutical Investment Opportunities & Case Studies.
Dr. Axel Polack, General Partner, TVM Capital |
|
| 10:10-10:30 |
Break |
| 10:30-12:00 |
VC Panel
How to Create Values and Opportunities by Connecting the Global Value Chain?
| Moderator |
| |
Dr. Johnsee Lee, President, ITRI |
| Panelists |
| |
Dr. Raju Kucherlapati, Harvard Medical School
Dr. Hong-Jen Chang, YFY Biotech Management Company
Ms. Elka Nir, Giza Venture Capital
Dr. Axel Polack, TVM Capital
Dr. David Bernstein, Bernstein CMC Regulatory Consulting
Dr. Timothy Rodell, GlobeImmune, Inc. |
|
| 12:00-13:00 |
Lunch |
| 13:00-16:00 |
Company Presentation - Biotech Investment Opportunities
Over 20 emerging biotech companies from Australia, Japan, Singapore, Canada, Thailand, USA, Germany, etc will present their Corporate and R&D overview in 4 sessions - New Drug Development , Anti-infective Therapeutics, R&D Service and Medical Device. It is a supreme opportunity for biotech companies, the major VC¡¦s, and investors from all over the world to meet one-on-one. |
| 16:00-17:00
|
One-On-One Meeting with 20 Companies |
| New Drug Development |
Anti-infective Therapeutics |
R&D Service |
Medical Device |
| Adjournment |
|
|
